Drug Type Biosimilar, Monoclonal antibody |
Synonyms Dupilumab Biosimilar (CSPC Megalith Biopharmaceutial Co., Ltd.), 度普利尤单抗生物类似药(石药集团巨石生物制药有限公司), SYS6033 |
Target |
Action inhibitors |
Mechanism IL-13 inhibitors(Interleukin-13 inhibitors), IL-4 inhibitors(Interleukin-4 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Moderate Atopic Dermatitis | Phase 1 | China | 03 Nov 2025 | |
| Severe Atopic Dermatitis | Phase 1 | China | 03 Nov 2025 |






